Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti PD L1 immune stimulating antibody conjugate - Bolt Biotherapeutics

Next Previous
Drug Profile

Anti PD L1 immune stimulating antibody conjugate - Bolt Biotherapeutics

Alternative Names: Anti-PD-L1 ISAC; PD-L1 Boltbody™ ISAC; PD-L1-ISAC

Latest Information Update: 13 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bolt Biotherapeutics
  • Class Antineoplastics; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Myeloid cell stimulants; T lymphocyte stimulants; Toll-like receptor 7 agonists; Toll-like receptor 8 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Head and neck cancer; Non-small cell lung cancer

Most Recent Events

  • 30 Apr 2025 Adverse events and pharmacodynamics data from a preclinical trial in Cancer released by Bolt Biotherapeutics
  • 10 May 2023 Bolt Biotherapeutics terminates its license with Stanford University for Boltbody™ platform (SEC File 2023- Bolt Biotherapeutics)
  • 17 Jan 2023 Preclinical trials in Breast cancer in USA (Parenteral) (Bolt Biotherapeutics pipeline, January 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top